Oruka Therapeutics Inc [ORKA] stock is trading at $33.4, up 2.77%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ORKA shares have gain 19.89% over the last week, with a monthly amount glided 15.41%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Oruka Therapeutics Inc [NASDAQ: ORKA] stock has seen the most recent analyst activity on December 18, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $75. Previously, Jefferies started tracking the stock with Buy rating on November 13, 2025, and set its price target to $45. On October 27, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $60 on the stock. Barclays started tracking the stock assigning an Overweight rating and suggested a price target of $48 on October 13, 2025. BTIG Research initiated its recommendation with a Buy and recommended $44 as its price target on May 22, 2025. Wolfe Research started tracking with an Outperform rating for this stock on February 04, 2025, and assigned it a price target of $20. In a note dated October 11, 2024, Stifel initiated a Buy rating and provided a target price of $49 on this stock.
Oruka Therapeutics Inc [ORKA] stock has fluctuated between $5.49 and $32.89 over the past year. Currently, Wall Street analysts expect the stock to reach $53 within the next 12 months. Oruka Therapeutics Inc [NASDAQ: ORKA] shares were valued at $33.4 at the most recent close of the market. An investor can expect a potential return of 58.68% based on the average ORKA price forecast.
Analyzing the ORKA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.28 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Oruka Therapeutics Inc’s Current Ratio is 16.94. Also, the Quick Ratio is 16.94, while the Cash Ratio stands at 4.35.
Transactions by insiders
Recent insider trading involved Goncalves Joana, Chief Medical Officer, that happened on Jan 15 ’26 when 7000.0 shares were sold. Chief Operating Officer, Sandler Laura Lee completed a deal on Jan 02 ’26 to sell 13000.0 shares. Meanwhile, Officer LAURA SANDLER bought 18000.0 shares on Jan 02 ’26.
